Solving Kids Cancer Inc

MAKE RADICAL IMPROVEMENTS IN SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS USING A PATIENT-CENTRIC APPROACH OF DRIVING/SUPPORTING HIGH-IMPACT CLINICAL RESEARCH, PRECLINICAL THERAPEUTIC DEVELOPMENT PROJECTS, CONDUCTING RESEARCH ADVOCACY IN THE LANDSCAPE AND EMPOWERING FAMILIES WITH RESOURCES/TOOLS TO HELP THEM NAVIGATE TREATMENT OPTIONS FOR THEIR CHILD.

SKC AND OUR ADVISORS SURVEY, DISCUSS AND PRIORITIZE THE GREATEST UNMET NEEDS WITHIN THE PEDIATRIC CANCER RESEARCH LANDSCAPE AND DEVELOP PROGRAMS TO ADDRESS THEM. (1) SKC TARGETS ONLY THE MOST CHALLENGING AND POOREST OUTCOME CHILDHOOD CANCERS THAT REQUIRE SIGNIFICANT HELP AND HAVE THE GREATEST UNMET NEED INCLUDING HIGH-RISK BRAIN TUMORS AND SOLID TUMORS. (2) TAKES A GLOBAL APPROACH TO SUPPORTING PROGRAMS TO LEVERAGE THE COLLECTIVE POWER OF COLLABORATION ACROSS SEVERAL CENTERS-OF-EXCELLENCE TO BREAK DOWN BARRIERS, SPEED PROGRESS AND HAVE MORE CHILDREN ACCESS PROMISING TREATMENTS. (3) PRIORITIZES ADVANCING TREATMENT OPTIONS THAT HAVE THE HIGHEST POTENTIAL FOR CURATIVE RESPONSES RATHER THAN PARTIAL TUMOR SHRINKAGE OR TEMPORARY LIFE EXTENSION. (4) TAKES LEADERSHIP ROLES WITHIN INFLUENTIAL NATIONAL AND INTERNATIONAL RESEARCH GROUPS' ADVISORY BOARDS AND CO-AUTHOR INFLUENTIAL PAPERS IN PROFESSIONAL JOURNALS TO DRIVE NEW DIRECTION TO POSITIVELY IMPACT PATIENTS. (5) IMPLEMENTS ADVOCACY AND ACTIVISM TO ENSURE THAT THE PATIENTS VOICE AND NEEDS ARE FRONT-AND-CENTER IN THE RESEARCH COMMUNITY'S AGENDAS AND PLANS. (6) DIRECTS RESEARCH FUNDING AND PROGRAMS TO THE FRONTLINES OF IMPACTING PEDIATRIC CLINICAL TRIALS AND DEVELOPING NEW TREATMENTS. (7) BUILD COALITIONS AND PARTNERSHIPS WITH OTHER NONPROFITS IN COLLABORATIVELY DRIVING AND FUNDING RESEARCH PROJECTS FOR GREATER IMPACT AND SCALE BECAUSE WE ARE MUCH MORE EFFECTIVE TOGETHER THAN WORKING ALONE.SURVIVAL RATES REMAIN UNSATISFACTORILY LOW FOR THE DEADLIEST CHILDHOOD CANCERS WHILE DECADES-OLD MODALITIES LIKE CHEMOTHERAPY AND RADIATION REMAIN THE PROMINENT STANDARDS-OF-CARE AND ARE NOT CURATIVE FOR NEARLY HALF OF HIGH-RISK PATIENTS. SKC FOCUSES ON ADVANCING NOVEL AGENTS/COMBINATIONS WITH THE HIGHEST CURATIVE RATIONALE WITHIN ALL PARTS OF THE TREATMENT CONTINUUM, STARTING IN CHILDREN WITH RELAPSE/REFRACTORY DISEASE, WITH A GOAL TO MOVE NEW TREATMENTS INTO FRONTLINE TREATMENT REGIMENS FOR NEWLY DIAGNOSED CHILDREN ESTABLISHING A GOLD STANDARD-OF-CARE IN A PERSONALIZED APPROACH PROVIDING THE RIGHT TREATMENTS TO THE RIGHT PATIENTS AT THE RIGHT TIME. SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY (VACCINES, CELLULAR THERAPY, ONCOLYTIC VIROTHERAPY, THERAPEUTIC ANTIBODIES, CHECKPOINT INHIBITORS), SYNERGISTIC COMBINATION TREATMENTS, NEW GENOMICALLY TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. SKC HAS SUPPORTED 28 CLINICAL TRIALS RESULTING IN 25 NEW EXPERIMENTAL TREATMENT OPTIONS FOR CHILDREN WITH HIGH-RISK CANCERS AND 16 PRECLINICAL DEVELOPMENT PROJECTS.OUR MOST RECENT PROGRAMS INCLUDE A NEW FRONTLINE CLINICAL TRIAL FOR HIGH RISK NEUROBLASTOMA INCORPORATING A GENOMICALLY TARGETED THERAPEUTIC IN COMBINATION WITH STANDARD-OF-CARE IN A MULTI-INSTITUTIONAL, GLOBAL TRIAL; A GLOBAL, MULTI-CENTER CLINICAL TRIAL FOR HIGH-RISK NEUROBLASTOMA USING A TRIPLET COMBINATION OF IMMUNOTHERAPY AND TARGETED RADIOTHERAPY FOR CHILDREN WHO RELAPSE; A MULTI-CENTER COLLABORATIVE PROGRAM TO DEVELOP A NEW PROGNOSTIC BIOMARKER SIGNATURE (ULTRA HIGH RISK) FOR NEUROBLASTOMA; A MULTI-CENTER PROGRAM TO DEVELOP A BIOMARKER SIGNATURE FOR INDOLENT (TREATMENT RESISTANT/REFRACTORY) TUMORS AND TEST A PIPELINE OF CANDIDATE COMBINATION THERAPIES, PROGNOSTIC BIOMARKER SIGNATURE (ULTRA HIGH RISK) FOR NEUROBLASTOMA; AND A NEW INITIATIVE FOR MEDULLOBLASTOMA TO IDENTIFY PROMISING COMBINATION THERAPIES THAT CROSS THE BLOOD-BRAIN BARRIER AS WELL AS NEW DELIVERY MECHANISMS.